EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients
| Autor: | Masahi Morioka, Toshiro Shirakawa, Tsutomu Nakamura, Shuji Terao, Mariko Yagi, Katsuhiko Okumura, Noboru Okamura, Yoshihiro Nishimura, Akinobu Gotoh, Toshiyuki Sakaeda, Kenji Tokui, Hisato Tanaka, Mitsuhiro Yokoyama |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Somatic cell Pharmaceutical Science urologic and male genital diseases Exon Gefitinib Germline mutation Japan Renal cell carcinoma medicine Humans Pharmacology (medical) Epidermal growth factor receptor RNA Messenger neoplasms Genotyping Carcinoma Renal Cell Pharmacology biology Organic Chemistry Middle Aged medicine.disease female genital diseases and pregnancy complications Kidney Neoplasms Up-Regulation ErbB Receptors Tumor progression Mutation Cancer research biology.protein Molecular Medicine Female Biotechnology medicine.drug |
| Zdroj: | Pharmaceutical research. 22(10) |
| ISSN: | 0724-8741 |
| Popis: | Heterozygous somatic mutations of epidermal growth factor receptor (EGFR) in exons 18, 19, and 21 were recently reported to be associated with response to gefitinib in patients having nonsmall cell lung cancer. Such mutations are more frequently found among Japanese than Europeans. In this work, the frequency of mutations was investigated in renal cell carcinoma (RCC) samples obtained from Japanese subjects to examine the potential of gefitinib as a therapeutic agent for RCC. Nineteen patients with RCC, who gave written informed consent, were enrolled in this study. mRNA expression levels of EGFR were measured in RCC and its adjacent noncancerous renal tissue via the real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) method. Somatic mutations were determined using genomic DNA extracted from RCC by direct sequencing method. mRNA expression was confirmed to be about 19 times higher in RCC than in adjacent noncancerous renal tissues, but no such mutations were detected in both. Results from this study do not support the validity of further clinical trials on gefitinib for RCC with genotyping even in Japanese patients, although EGFR plays a key role in tumor progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink